CA2454578C - Modified human thymic stromal lymphopoietin - Google Patents

Modified human thymic stromal lymphopoietin Download PDF

Info

Publication number
CA2454578C
CA2454578C CA2454578A CA2454578A CA2454578C CA 2454578 C CA2454578 C CA 2454578C CA 2454578 A CA2454578 A CA 2454578A CA 2454578 A CA2454578 A CA 2454578A CA 2454578 C CA2454578 C CA 2454578C
Authority
CA
Canada
Prior art keywords
seq
tslp
polypeptide
amino acids
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2454578A
Other languages
English (en)
French (fr)
Other versions
CA2454578A1 (en
Inventor
Stewart D. Lyman
Kirk P. Van Ness
Raymond J. Paxton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of CA2454578A1 publication Critical patent/CA2454578A1/en
Application granted granted Critical
Publication of CA2454578C publication Critical patent/CA2454578C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2454578A 2001-07-23 2002-07-23 Modified human thymic stromal lymphopoietin Expired - Lifetime CA2454578C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30734501P 2001-07-23 2001-07-23
US60/307,345 2001-07-23
PCT/US2002/023475 WO2003032898A2 (en) 2001-07-23 2002-07-23 Modified human thymic stromal lymphopoietin

Publications (2)

Publication Number Publication Date
CA2454578A1 CA2454578A1 (en) 2003-04-24
CA2454578C true CA2454578C (en) 2013-06-25

Family

ID=23189325

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2454578A Expired - Lifetime CA2454578C (en) 2001-07-23 2002-07-23 Modified human thymic stromal lymphopoietin

Country Status (11)

Country Link
US (9) US7288633B2 (enExample)
EP (1) EP1417231B1 (enExample)
JP (2) JP5329016B2 (enExample)
AU (1) AU2002359238B2 (enExample)
CA (1) CA2454578C (enExample)
DK (1) DK1417231T3 (enExample)
ES (1) ES2422879T3 (enExample)
MX (1) MXPA04000631A (enExample)
PL (1) PL371773A1 (enExample)
PT (1) PT1417231E (enExample)
WO (1) WO2003032898A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
ATE555194T1 (de) * 2001-12-18 2012-05-15 Cancer Rec Tech Ltd Methode zur herstellung von proliferierenden und differenzierenden zelllinien
SI1651247T1 (sl) * 2003-07-18 2009-02-28 Schering Corp Zdravljenje in diagnoza neoplazem z uporabo timusnega stromalnega limfopoietina
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
SE532251C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
WO2009032954A1 (en) * 2007-09-04 2009-03-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
GB0918782D0 (en) * 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
ES2784123T3 (es) 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
HRP20210650T1 (hr) 2015-09-09 2021-05-28 Novartis Ag Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
US11001624B2 (en) 2016-04-05 2021-05-11 Vib Vzw TSLP inhibitors
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
ATE188610T1 (de) 1992-04-30 2000-01-15 Amgen Inc Methoden zur behandlung von interleukin- 1 und - tumor - nekrose - faktor - verursachten krankheiten
GB9209874D0 (en) 1992-05-07 1992-06-24 Ml Lab Plc Pharmaceutical compositions
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
JP2002526079A (ja) 1998-09-21 2002-08-20 シェーリング コーポレイション ヒトインターロイキン−ｂ５０、治療的使用
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
EP1140976A4 (en) 1998-12-30 2003-05-21 Millennium Pharm Inc SECRETED PROTEINS AND THEIR USES
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1712239A3 (en) 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
US6955895B2 (en) 2000-06-28 2005-10-18 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
PL371773A1 (en) 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
GB2381685A (en) 2001-10-30 2003-05-07 Amino Holdings Ltd Gateway device for converting digital signals to analogue signals
AU2003208888B2 (en) * 2002-02-01 2006-10-19 Merck Sharp & Dohme Llc Uses of mammalian cytokine; related reagents
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
SI1651247T1 (sl) 2003-07-18 2009-02-28 Schering Corp Zdravljenje in diagnoza neoplazem z uporabo timusnega stromalnega limfopoietina
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
EP1793856A2 (en) 2004-08-20 2007-06-13 Amgen Inc. Methods and compositions for treating allergic inflammation
CA2635599C (en) 2006-01-13 2014-06-17 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
CN102027012A (zh) 2007-06-20 2011-04-20 Irm责任有限公司 用于治疗变应性疾病的方法和组合物

Also Published As

Publication number Publication date
US20100167393A1 (en) 2010-07-01
PT1417231E (pt) 2013-07-29
US20140093956A1 (en) 2014-04-03
US20210102955A1 (en) 2021-04-08
US8598318B2 (en) 2013-12-03
US9045558B2 (en) 2015-06-02
US7288633B2 (en) 2007-10-30
US7709217B2 (en) 2010-05-04
ES2422879T3 (es) 2013-09-16
EP1417231A2 (en) 2004-05-12
MXPA04000631A (es) 2004-06-25
US20070218523A1 (en) 2007-09-20
US20160377630A1 (en) 2016-12-29
US20110230637A1 (en) 2011-09-22
CA2454578A1 (en) 2003-04-24
US20150252089A1 (en) 2015-09-10
JP2010279365A (ja) 2010-12-16
AU2002359238B2 (en) 2008-01-17
EP1417231B1 (en) 2013-06-19
DK1417231T3 (da) 2013-07-22
PL371773A1 (en) 2005-06-27
WO2003032898A3 (en) 2003-08-14
JP2005505293A (ja) 2005-02-24
US20130023647A1 (en) 2013-01-24
US20080145866A1 (en) 2008-06-19
EP1417231A4 (en) 2004-12-15
US7973151B2 (en) 2011-07-05
JP5329016B2 (ja) 2013-10-30
WO2003032898A2 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
US8598318B2 (en) Modified human thymic stromal lymphopoietin
US5552303A (en) DNA encoding epithelium-derived T-cell factor
CA2186747C (en) Interleukin-15
AU2002359238A1 (en) Modified human thymic stromal lymphopoietin
JP2010187691A (ja) 哺乳類のトランスフォーミング増殖因子β−９
US20040047873A1 (en) Materials and methods relating to the increase in protein activity
EP1451333B1 (en) Ul16 binding protein 4
KR20220044577A (ko) T-조절 세포의 확장을 위한 인터류킨-2 돌연변이단백질
US20090010872A1 (en) Chimeric soluble hyper il-11 and use thereof
KR20000052812A (ko) 다기능 키메라 조혈 수용체 아고니스트
AU6767394A (en) Interleukin-15
US20070081979A1 (en) Multi-functional chimeric hematopoietic receptor agonists
JP3689111B2 (ja) インターロイキン１５
JP2007236387A (ja) 精製タンパク質の製造方法
JP2007238605A (ja) 精製タンパク質の製造方法
JP2007238606A (ja) 精製タンパク質の製造方法

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220725